Postoperative opioids, endocrine changes, and immunosuppression by Haroutounian, Simon




Postoperative opioids, endocrine changes, and
immunosuppression
Simon Haroutounian
Washington University School of Medicine in St. Louis
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Haroutounian, Simon, ,"Postoperative opioids, endocrine changes, and immunosuppression." Pain Reports.3,2. e640. (2018).
https://digitalcommons.wustl.edu/open_access_pubs/6832




“The pathetically grim and perspiring patient, fearful of
moving or breathing, has become a constant fixture on
postsurgical wards. His suffering was anticipated by his
physician and is accepted in the knowledge that it will
disappear in time.”22
Acute postoperative pain is considered an unavoidable conse-
quence of a surgery, and is somewhat anticipated, given the
(typically) massive tissue injury, inflammation, and stress response
as a result of a surgical procedure. However, it is well documented
that the “perspiring patient, who is fearful of moving or breathing,”
ie, the patient who suffers from severe postoperative pain, is more
prone to adverse outcomes. Patients, in whom severe pain impairs
breathing, coughing, physical therapy, and early mobilization, are
more likely to develop complications such as respiratory infections
and thromboembolic events. The pain is also a significant stressor
both from the psychological and physiological points of view.
The responses of the central nervous system and the
hypothalamus-pituitary-adrenal (HPA) axis to a perceived stress
involve a complex network of signaling molecules, including
endorphins, catecholamines, and cortisol. The stress response to
surgery is characterized by activation of HPA axis, as reflected by
increased secretion of hypothalamic corticotropin-releasing
hormone (CRH), and subsequently increased levels of adreno-
corticotropic hormone (ACTH) and cortisol. In addition, surgical
stress enhances the secretion of other catabolically active
hormones, mainly catecholamines and glucagon, but also
prolactin, growth hormone, and b-endorphin.42
The enhanced postsurgical stress response, which leads to
high cortisol levels, can result in immunosuppression,33 support-
ing the notion that the relief of pain should be beneficial in
preventing, eg, postoperative infections.33 In the setting of cancer
surgery, the immune function may have even further implications,
as animal studies have shown that surgery-induced stress is
associated with impaired natural killer (NK) lymphocyte activity,
impairing the body’s ability to clear tumor cells.33
Although the description of a grim, perspiring, and suffering
patient as a constant fixture may not have been surprising in the
1950s, one would expect that the development of novel drugs
and multimodal analgesia approaches in the past few decades
would dramatically improve the quality of postoperative pain
management, and reduce the undesired hormonal and in-
flammatory consequences associated with the surgical stress.
However, current data from inpatient and outpatient surgical
settings indicate that between 30% and 50% of postoperative
patients consistently experience moderate to severe pain.19,35,36
2. The role of opioids in the management of acute
postoperative pain
Opioids are the most commonly used drugs for the management
of acute postoperative pain. Depending on the setting and type of
surgery, opioids are delivered systemically either through
scheduled or pro re nata (as needed) dosing, or through
a patient-controlled analgesia device. Alternatively, the post-
operative opioid regimen may include neuraxial delivery through
an epidural catheter, as a part of patient-controlled epidural
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Key Points
1. Surgery is associated with a massive inflammatory and
stress response. Untreated postoperative pain results in
immunosuppression, increases the risk of thromboem-
bolic events, and delays recovery.
2. Chronic opioid therapy results in major endocrine changes
such as opioid-induced androgen deficiency and bone
demineralization. The clinical relevance of these phenom-
ena with short-term opioid use for postoperative pain is
unclear.
3. In the surgical setting, high-dose opioidsmay contribute to
inhibition of immune responses and curbing of stress
response (eg, cortisol rise), but the clinical consequences
of these observations are still unclear.
4. Multimodal postoperative approaches, especially those
combining regional anesthesia with local anesthetics, help
improve pain scores and reduce postoperative opioid
requirements; however, contradictory data exist on their
effect in reducing immune-mediated complications such
as infections or tumor dissemination.
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analgesia (PCEA) technique. Mostly, opioids that are used for
acute postoperative pain relief, include the short-acting mor-
phine, hydromorphone, oxycodone (in countries where paren-
teral formulation is available), and occasionally fentanyl or
tramadol (which is a weak opioid agonist and a serotonin–
norepinephrine reuptake inhibitor).
Opioids are very effective in treating acute postoperative pain;
however, not without important side effects. Among their most
commonly observed and reported adverse effects in this setting
are nausea, vomiting, sedation, pruritus, and constipation. The
more severe undesired outcome is respiratory depression, which
is potentially life-threatening, and is the most feared side effect of
opioid medications. The brainstem control of respiratory rate and
tidal volume is driven by afferent input of partial pressure of arterial
O2 (through chemosensors in carotid and aortic bodies) and CO2
(through chemosensors in the brainstem). Opioids, through
m-opioid receptor-mediated depression of excitability of brain-
stem chemosensory neurons, depress the ventilatory response
to increased CO2, thus depressing respiration.
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3. Literature search methodology and focus
This update will focus on a different subset of effects associated
with the use of opioid analgesics in the acute postoperative
setting; these are endocrine changes and immunosuppression.
This clinical update will discuss the evidence behind the role of
opioids in contributing to each of these phenomena in the
postoperative setting, discuss their clinical relevance, and
summarize the recent data on approaches that could be
considered when treating pain in patients after surgery.
To provide systematicity to literature retrieval, PubMed search
was performed in September 2017 with the following keywords:
“opioids” (All Fields) AND “surgery” (All Fields) AND “pain” (All Fields)
AND (“immune suppression” [All Fields] OR endocrine” [All Fields]).
The search resulted in 125articles,whichwere screened for relevant
information, including articles identified from their reference lists.
To obtain a comprehensive evaluation of opioid effects in the
perioperative setting, information on both postoperative opioids
for pain relief and data on intraoperative opioids for analgesia/
anesthesia purposes were considered. As rapid recovery from
anesthesia is becoming an increasingly important outcome,
opioids with faster offset such as remifentanil and sufentanil are
used more commonly, but (especially remifentanil) may be
associated with certain adverse effects.
4. Major endocrine changes associated with opioids
The current evidence suggests that opioids cause endocrine
changes by 2 major mechanisms:
(1) Opioids affect the hypothalamic-pituitary-gonadal (HPG) axis.
(2) Opioids affect the HPA axis.
The impact on the HPG axis is a well-described dose-
dependent effect of opioids, particularly related to treatment with
daily doses above 100 to 200mg of oral morphine equivalents for
more than a few weeks. The HPG cascade is initiated by the
release of gonadotropin-releasing hormone (GnRH) from the
hypothalamus, which stimulates the anterior pituitary to release
luteinizing hormone (LH) and follicle-stimulating hormone (FSH),
which stimulate the gonads to produce testosterone and
estrogen. Opioids bind to m-opioid receptors in the hypothala-
mus, inhibiting the release of GnRH, thus decreasing LH and FSH
secretion from the pituitary. Subsequently, this leads to decrease
in testosterone levels and hypogonadism, a condition typically
referred to as opioid-induced androgen deficiency (OPIAD).29
Opioid-induced androgen deficiency is a significant observa-
tion in the setting of chronic opioid therapy, affecting 53% to 90%
of male patients on chronic opioid therapy.29 The long-term
symptoms of OPIAD in this setting include decreased attention,
decreased libido, fatigue, erectile dysfunction, and osteoporosis.
In women receiving chronic opioids, LH and FSH levels are
markedly reduced and are associated with amenorrhea and
impaired adrenal androgen production.13
Some studies have questioned the suggestion that OPIAD is
associated only with chronic opioid therapy. Several animal studies
have shown that even acute opioid administration (eg, morphine,
fentanyl, and buprenorphine), especially at high doses, results in
reduced levels of testosterone,10 but the duration of this effect is
reported to last between24hours toup to8weeksafter treatment.11
A significant drop in total testosterone level in humans is also
observed with a single $30 mg dose of methadone, or within 24
hours of perioperative morphine administration.30,41
Unfortunately, well-designed studies aimed at understanding
the mechanisms of testosterone suppression, and the clinical
relevance of short-term hypogonadism in the setting of acute
opioid administration are lacking. Moreover, surgical stress may
also contribute to these phenomena, and patients receiving
ketamine (and not morphine) analgesia still display reduced
testosterone plasma levels.30 Therefore, more careful studies are
warranted to dissect themagnitude and the importance of OPIAD
in the perioperative setting.
The impact of the opioids on the HPA axis is less well
described. The HPA cascade is initiated by CRH release from the
hypothalamus, which stimulates the pituitary to release ACTH to
the systemic circulation, stimulating, in turn, the adrenal glands to
produce 2 hormones—dehydroepiandrosterone (DHEA) and
cortisol. Opioids seem to inhibit the functioning of the entire
HPA axis. On one hand, they reduce the production/release of
CRH, and on the other, they decrease the responsiveness of the
anterior pituitary to CRH. Both processes lead to reduced ACTH
secretion. Independently, opioids may also directly interfere with
the adrenal gland production of cortisol and DHEA. Cortisol is
important for mounting stress responses, and DHEA is an
important precursor for testosterone (in men) and estradiol (in
women).
The mechanistic data on opioid-associated changes in HPA
axis come primarily from rodent and healthy volunteer experi-
ments. For example, in healthy volunteers, single-dose morphine
suppresses ACTH and cortisol levels both at baseline and after
CRH stimulation.2 However, the extrapolation of healthy volun-
teer data to the surgical setting is not straightforward, as the
surgical stress, and the postoperative pain per se, can have
a substantial effect on the functionality of the HPA axis. The
surgery typically results in an increased stress response, which
subsides after about 24 hours. Certain opioids (remifentanil,
particularly) are reported to acutely suppress plasma cortisol in
a dose-dependent manner.1 In the setting of elective C-section,
remifentanil administered as a bolus followed by continuous
intraoperative infusion (compared with fentanyl administration
after delivery) partially obtunded the neuroendocrine response to
surgery with a decrease in ACTH rise (but not in norepinephrine,
epinephrine, and growth hormone).14
The association between opioids and blunting ACTHor cortisol
rise seems to be modest at best, and highly dependent on the
timeframe of the assessment. In addition, some studies failed to
find changes in cortisol levels after intraoperative remifentanil
infusion.3 As in the case of reduced testosterone concentrations,
the clinical relevance of altered cortisol levels in the setting of
perioperative opioid therapy is not clear.
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5. Opioids and immune response—inflammation
and infections
Opioids do not possess strong anti-inflammatory properties
such as nonsteroidal anti-inflammatory drugs or corticosteroid
drugs, and their potential effects on inflammatory responses
seem to be highly dependent on the setting. For example, in
patients undergoing coronary artery bypass graft procedure,
administration of continuous remifentanil infusions (vs intermit-
tent fentanyl dosing) resulted in lower levels of proinflammatory
cytokines (such as TNF-a and IL-6) at some time points after
cardiopulmonary bypass. Eight hours after surgery, however, no
differences were observed between the groups.40 On the
contrary, some studies have reported lower inflammatory
response (lower C-reactive protein level) with opioid-
minimizing analgesia in the setting of colorectal surgery38 or
enhanced proinflammatory cytokine release in the spinal cord
as a response to opioid challenge. The clinical relevance of
these short-term effects of opioids on inflammatory markers
remains to be investigated.
The 2 main areas of research focused on opioid-associated
immune effects deal with (1) the effects of opioids on immune
response to infections; and (2) opioid effects on tumor-specific
immune responses, affecting tumor growth and dissemination.
Major histocompatibility complex, class II (MHC-II) molecules,
expressed on antigen-presenting cells, are important regulators
of immune cell development and function. Morphine has been
shown to alter gene expression of the MHC-II in circulating
immunocytes (Beagles 2004), and thus suspected in causing
immunosuppression. It is a matter of debate whether these
effects aremediated by opioid-induced alteration in cortisol levels
(as in adrenalectomized rats, morphine exposure does not affect
MHC-II), or there is a direct immunosuppressive effect attribut-
able to opioids. Interestingly, morphine withdrawal results in
renewed increase in circulating corticosterone levels and
a renewed suppression of MHC-II in previously opioid-tolerant
animals.28
The risk of surgical site infection was higher after abdominal
surgery with remifentanil anesthesia vs fentanyl anesthesia.21 The
findings could be attributable to more substantial immunosup-
pression with remifentanil (although direct data are lacking), or to
opioid withdrawal, which is more likely with the short-acting
remifentanil. Additional data support this notion of immunosup-
pression associated with opioid withdrawal; for example,
remifentanil discontinuation increased the risk of intensive care
unit–acquired infection,27 and morphine withdrawal in mice (after
96-hour exposure) increased the risk of infection in an experi-
mental model of septic shock. Interestingly, the most commonly
detected organisms in tissue of morphine-withdrawn mice were
bacteria that are part of the normal gastrointestinal flora.18 There
are additional rodent studies suggesting that morphine, by
altering gut microbiome, may increased the risk of sepsis by
bacterial dissemination.24
A review examining whether opioids increase the risk of
infections in the perioperative or intensive care setting, suggested
that patients receiving higher doses of systemic opioids had an
increased risk of developing pneumonia perioperatively.32
However, these results are not universal and were observed only
if laparoscopic vs open surgery (or epidural vs systemic opioid
therapy) was compared.
Overall, the data are both inconsistent and insufficient to
determine the extent of opioid-associated immune suppression
on infectious complications after surgery. Untreated pain itself
can increase the risk of infections, eg, because of impaired
mobility; pain also enhances the body’s stress response, which
by enhancing circulating cortisol, can contribute to immunosup-
pression. It needs to be taken into account that low-dose opioid
control groups in some studies (eg, epidural analgesia and
laparoscopic surgeries) could have better quality of analgesia and
improved ability to clear secretions. It is also possible that
increased risk of infection is among the immunological sequelae
of opioid withdrawal, rather that opioid therapy, per se. The
microbiome-related effects of opioids (and the potential dissem-
ination of gut microorganisms) are another area that requires
additional research. Although some studies suggest that
buprenorphine (partial m-opioid agonist and a k-opioid antago-
nist) may be devoid of immunosuppressive effects,33 whether
different opioids have differential effects on immune function still
requires detailed investigation.
6. Opioids and immune response—cancer
Opioids can suppress NK cell cytotoxicity. Both high-dose and
low-dose fentanyl suppressed NK cytotoxicity for 24 hours.5
However, rate of recovery of NK cell suppression was longer in
the high-dose fentanyl group. Rats, which were treated with 20
mg/kg morphine (vs saline), developed a decrease in B-
lymphocyte blood expression of MHC class II molecules within
2 hours.4 The same group has previously reported that in rats,
fentanyl suppresses NK cell cytotoxicity and increases the risk of
tumor metastases.34 Although there might be a dose-dependent
effect, it is not clear whether different opioids affect the NK
function differentially. In this regard, data suggest that endoge-
nous opioids (b-endorphin) inhibit T-cell proliferation to a lesser
extent than exogenous morphine.15
Despite these experimental findings, it is unclear whether there
is any long-term immunosuppression associated with similar
changes in antigen-presenting cells in humans.
A large retrospective analysis of a national registry data from
Denmark (n 5 34,188) showed no difference of breast cancer
recurrence as a function of opioid use.12 The researchers
categorized “strong immunosuppressive opioids (codeine, mor-
phine, and fentanyl) vs weakly immunosuppressive opioids
(oxycodone, tramadol, buprenorphine, and hydromorphone),”
based on previous literature, but found no difference between the
groups.
Considering the immunosuppressive effects attributable to
pain and the enhanced stress response (and cortisol increase),
which opioids may blunt, it is currently unclear whether the
clinically relevant “net effect” of postoperative pain management
with opioids tips the immune balance towards immune suppres-
sion. There is also insufficient evidence to determine that some
opioids produce strong immunosuppressive effects, whereas
others produce only weak or no such effects.
7. Mitigation approaches
7.1. Stress response and inflammation
Inflammatory reaction after surgery is a physiological response
that helps the healing process. An excessive inflammatory
response can lead to complications, but immune suppression
could negatively affect the healing process. With potential effects
of opioids on inflammation, and potential immunosuppressant
activity, the attempt in the recent years has been to use
multimodal analgesia approaches that provide adequate analge-
sia, but avoid excessive opioid use, especially high-dose intra-
operative remifentanil.
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Patient-controlled epidural analgesia (with bupivacaine and
fentanyl) after lower abdominal surgery have resulted in blunted
postoperative elevation of cortisol and prolactin, and lower pain
scores, compared with other opioid-only systemic analgesia
regimens.42
In a setting of retropubic prostatectomy, PCEA (with ropiva-
caine and sufentanil) resulted in lower pain intensity, and reduced
the postoperative stress response (plasma cortisol and glucose),
but not the acute inflammatory response (TNF-a and IL-6
levels).17
Another study in 24 women undergoing laparoscopic chole-
cystectomy assessed the effect of a single-dose intrathecal
(bupivacaine with fentanyl) vs epidural (ropivacaine with fentanyl)
anesthesia, before general anesthesia in both groups.7 Intra-
operative cortisol, noradrenaline, and total catecholamine levels
were significantly lower in the intrathecal (spinal) anesthesia group
(and patients required less systemic fentanyl); ie, spinal anaes-
thesia produced a more favourable endocrine response than
epidural anaesthesia.
In pediatric cardiac surgery, on the other hand, high-dose
intraoperative fentanyl has demonstrated better (lower) profile of
stress markers such as ACTH, glucose, cortisol, and lactate,
compared with low-dose fentanyl. High-dose intraoperative
fentanyl also resulted in lower postoperative opioid
requirements.26
The available results demonstrate that neuraxial anesthesia
and analgesia (intrathecal route perhaps more advantageous
than epidural), result in either lower pain scores or less systemic
opioid requirements, and can blunt the stress response, with
minimal effect on acute inflammatory response. This suggests
that multimodal anesthesia with neuraxial opioid and local
anesthetic delivery, where possible, may provide advantage to
systemic (especially high-dose) opioid administration. The
advantages in the pediatric surgery setting have not been
explored sufficiently and merit more thorough investigation.
7.2. Cancer
The literature is divided on the topic of regional anesthesia
approaches and their potential effect on cancer-related out-
comes. Initial retrospective studies reported that perioperative
use of regional (neuraxial or peripheral) anesthesia is associated
with improved outcomes in terms of cancer recurrence and
survival after breast and prostate surgery.6,16
However, a later retrospective study in colorectal cancer
surgery,20 an ad hoc analysis of a prostatectomy study,37 and
a retrospective study in lung cancer did not show any benefit of
regional anesthesia on cancer-related outcomes.9 A prospec-
tive randomized controlled trial25 did not demonstrate pro-
longed survival in major abdominal surgery, and a recent
retrospective study in patients undergoing radical cystectomy
for bladder cancer demonstrated more than 50% reduction in
perioperative opioid consumption with spinal anesthesia, but
this difference was not associated with changes in outcomes
such as all-cause mortality, bladder cancer mortality, or cancer
recurrence.39
A prospective study8 found that innate immunity (NK cells,
CD41, and CD81 cells) was depressed in lung cancer patients
undergoing resection, but postoperative epidural analgesia did
not help preserve the immunity.
In addition, a recent systematic review of the literature (15
studies) found inconclusive evidence to support or refute the
suggestion that paravertebral blocks in breast cancer can reduce
cancer recurrence or improve survival.
Currently, there is no conclusive evidence that regional
anesthesia, by either reducing opioid doses or by other
mechanisms such as sympathetic blockade, can improve long-
term cancer-related outcomes in cancer patients undergoing
surgery. With that said, there is no major disadvantage in using
regional techniques, and the opioid-sparing and stress
response–blunting acute effects justify the widespread use of
such approaches for postoperative pain relief.
8. Critical questions to be addressed by
future research
The undesired effects attributable to opioids, which were
discussed in this article, are often challenging to address, as
some of these effects may be related to surgical stress or
postoperative pain, per se. For example, endogenous opioids
such as beta-endorphins play an important role in the regulation
of gonadotropins through modulation of GnRH pulse amplitude
and frequency. Therefore, with the question of OPIAD inmind, it is
critical to control for this variable, as some data suggest that
testosterone levels are lower in subjects with pain compared with
controls, irrespective of opioid use.23 Are then patients, who are
inmore pain (and therefore are likely to require higher opioid dose)
more likely to develop endocrine adverse effects? What is then
the contribution of pain vs opioid (type and dose)? Is it more
important to control the pain well, or avoid high-dose opioids,
even at the expense of higher pain? These research questions are
yet to be answered and need to be address accurately to move
the field forward, toward safer and more rational perioperative
opioid use.
In a similar scenario, severe pain is associated with enhanced
stress response, accompanied by catecholamine and cortisol
release. Numerous preclinical and clinical studies have focused
on the effect of opioid analgesics on the postoperative stress
response. As enhanced stress response may cause immune
suppression and lead to postsurgical complications, blunting
the stress response has been historically considered as a desir-
able perioperative outcome. However, the advantages of
blunting the stress response with opioids should be weighed
against potential immunosuppression, and more research is
needed to achieve an optimal balance that would positively
affect patient outcomes.
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